CSL CEO on Results, Global Business Outlook

Aug. 14 (Bloomberg) -- Paul Perreault, chief executive officer of CSL Ltd., the world’s second-biggest maker of blood-derived therapies, talks about the company's financial performance and business outlook. CSL, reported a 19 percent jump in annual profit, boosted by demand in the U.S. and Europe for Hizentra, an infection-fighting infusion. Perreault speaks with Susan Li on Bloomberg Television's "First Up." (Source: Bloomberg)
Equity Valuations Lofty, Earnings Lousy: Morganlander
51:46 - Stifel Nicolaus' Chad Morganlander and Bloomberg's Michael Regan discuss the global selloff in stocks with Bloomberg's Pimm Fox on "Taking Stock." (Source: Bloomberg)
  • `Time Is of the Essence' for Greece to Reach Deal: Lew
  • A Penthouse Perspective on NYC Real Estate
  • Will the Comcast-Time Warner Cable Merger Ever Happen?